Sensus Healthcare (NASDAQ:SRTS) issued its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, Fidelity Earnings reports. The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $7.77 million. Sensus Healthcare had a negative net margin of 8.65% and a negative return on equity of 8.82%.
NASDAQ SRTS traded down $0.21 during trading hours on Friday, hitting $3.80. The company had a trading volume of 73,900 shares, compared to its average volume of 31,014. Sensus Healthcare has a 1-year low of $3.71 and a 1-year high of $9.23. The company has a market cap of $93.54 million, a PE ratio of -27.14 and a beta of -0.41. The business has a 50 day moving average of $5.73 and a 200-day moving average of $5.72.
SRTS has been the subject of a number of analyst reports. ValuEngine downgraded shares of Sensus Healthcare from a “buy” rating to a “hold” rating in a research note on Thursday, October 17th. TheStreet upgraded shares of Sensus Healthcare from a “d+” rating to a “c-” rating in a research note on Monday, August 26th. B. Riley downgraded shares of Sensus Healthcare from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $14.00 to $5.50 in a research note on Thursday. Maxim Group set a $11.00 target price on shares of Sensus Healthcare and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Sensus Healthcare in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $8.30.
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Read More: What are CEFs?
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.